Location History:
- Bay Shore, NY (US) (2009 - 2011)
- Staten Island, NY (US) (2013 - 2014)
- Tarrytown, NY (US) (2023)
Company Filing History:
Years Active: 2009-2023
Title: Innovations of Irene Noguera-Troise
Introduction
Irene Noguera-Troise is a prominent inventor based in Bay Shore, NY (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of human antibodies. With a total of seven patents to her name, her work focuses on advancing therapeutic methods for combating tumor growth and cancer.
Latest Patents
One of her latest patents is titled "Human antibodies to human delta like ligand 4." This invention provides methods for treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis. It involves administering a human antibody or fragment that specifically binds to human delta-like ligand 4 (hDll4) and blocks its binding to a Notch receptor. The anti-hDll4 antibody exhibits a high affinity with a Kof of 500 pM or less, as measured by surface plasmon resonance. Another significant patent is "Method of treating cancer with DLL4 antagonist and chemotherapeutic agent." This invention outlines methods for treating various types of cancer by administering a combination of Dll4 antagonists and chemotherapeutic agents. The combination therapies demonstrate synergistic effects, particularly beneficial for cancer patients with low tolerance to side effects from high dosages.
Career Highlights
Irene Noguera-Troise is currently associated with Regeneron Pharmaceuticals, Inc., where she continues to innovate in the field of cancer therapeutics. Her work has been instrumental in developing new treatment methodologies that enhance patient outcomes.
Collaborations
Irene has collaborated with notable colleagues, including Gavin Thurston and Eric L. Smith, contributing to the advancement of cancer treatment research.
Conclusion
Irene Noguera-Troise's innovative work in developing human antibodies and treatment methodologies has made a significant impact in the field of cancer research. Her contributions continue to pave the way for new therapeutic options for patients battling cancer.